Leaps by Bayer and RA Capital led a $100m Series C round in Boundless Bio.

Leaps by Bayer, the impact investment arm of Bayer, and RA Capital, an investment company, led a $100m Series C round in Boundless Bio, a clinical stage, next-generation precision oncology company, with participation from Sectoral Asset Management, Piper Heartland Healthcare Capital, Fidelity Management & Research Company LLC, ARCH Venture Partners, Nextech Invest, Wellington Management, Vertex Ventures HC, Redmile Group, Surveyor Capital, GT Healthcare Capital Partners, Alexandria Venture Investments, PFM Health Sciences, Logos Capital, and City Hill Ventures. “At Leaps by Bayer, we invest in fundamental breakthroughs in healthcare. The ability to address oncogene amplified cancers has remained one of the industry’s greatest challenges in the treatment of cancer. We are thrilled to support Boundless Bio, a company whose innovations have the potential to impact the lives of patients who currently have no effective standard of care," Juergen Eckhardt, Leaps by Bayer EVP.